Chữ ký gen 70 với nguy cơ cao không liên quan đến việc phát hiện sự lan tỏa của tế bào khối u đến tủy xương

Hosseini H, Obradović MMS, Hoffmann M et al (2016) Early dissemination seeds metastasis in breast cancer. Nature. https://doi.org/10.1038/nature20785 Olivotto IA, Bajdik CD, Ravdin PM et al (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716–2725. https://doi.org/10.1200/JCO.2005.06.178 Wishart GC, Bajdik CD, Dicks E et al (2012) PREDICT plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 107:800–807. https://doi.org/10.1038/bjc.2012.338 Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800. https://doi.org/10.1056/NEJMra0801289 van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536. https://doi.org/10.1038/415530a van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A Gene-Expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009. https://doi.org/10.1056/NEJMoa021967 Buyse M, Loi S, van’t Veer L et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183–1192. https://doi.org/10.1093/jnci/djj329 Cardoso F, van’t Veer LJ, Bogaerts J et al (2016) 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375:717–729. https://doi.org/10.1056/NEJMoa1602253 Schlimok G, Funke I, Holzmann B et al (1987) Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci 84:8672–8676. https://doi.org/10.1073/pnas.84.23.8672 Müller P, Weckermann D, Riethmüller G, Schlimok G (1996) Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. Cancer Genet Cytogenet 88:8–16. https://doi.org/10.1016/0165-4608(95)00189-1 Husemann Y, Geigl JB, Schubert F et al (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58–68. https://doi.org/10.1016/j.ccr.2007.12.003 Schmidt-Kittler O, Ragg T, Daskalakis A et al (2003) From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci 100:7737–7742. https://doi.org/10.1073/pnas.1331931100 Hartkopf AD, Taran FA, Wallwiener M et al (2014) Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients—results from a large single-centre analysis. Eur J Cancer 50:2550–2559. https://doi.org/10.1016/j.ejca.2014.06.025 Domschke C, Diel IJ, Englert S et al (2013) Prognostic value of disseminated tumor cells in the bone marrow of patients with operable primary breast cancer: a long-term follow-up study. Ann Surg Oncol 20:1865–1871. https://doi.org/10.1245/s10434-012-2814-4 Braun S, Vogl FD, Naume B et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802. https://doi.org/10.1056/NEJMoa050434 Fehm T, Braun S, Muller V et al (2006) A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107:885–892. https://doi.org/10.1002/cncr.22076 Lips EH, Mukhtar RA, Yau C et al (2012) Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat 136:35–43. https://doi.org/10.1007/s10549-012-2233-z Straver ME, Glas AM, Hannemann J et al (2010) The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 119:551–558. https://doi.org/10.1007/s10549-009-0333-1 Hartkopf AD, Wallwiener M, Kommoss S et al (2016) Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score. Breast Cancer Res Treat 156:91–95. https://doi.org/10.1007/s10549-016-3728-9 Bartlett JMS, Bayani J, Marshall A et al (2016) Comparing breast cancer multiparameter tests in the optima prelim trial: no test is more equal than the others. J Natl Cancer Inst 108:1–9. https://doi.org/10.1093/jnci/djw050 Kim C, Baker J, Ph D et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826. https://doi.org/10.1056/NEJMoa041588 Meng S, Tripathy D, Frenkel EP et al (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10:8152–8162. https://doi.org/10.1158/1078-0432.CCR-04-1110 Janni WJ, Rack B, Terstappen LWMM et al (2016) Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res 22:2583–2593. https://doi.org/10.1158/1078-0432.CCR-15-1603 Lucci A, Hall CS, Lodhi AK et al (2012) Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13:688–695. https://doi.org/10.1016/S1470-2045(12)70209-7 Bidard F-C, Proudhon C, Pierga J-Y (2016) Circulating tumor cells in breast cancer. Mol Oncol 10:418–430. https://doi.org/10.1016/j.molonc.2016.01.001 Buus R, Sestak I, Kronenwett R et al (2016) Comparison of endopredict and epclin with oncotype dx recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst 108:1–7. https://doi.org/10.1093/jnci/djw149